| 1.6 -0.15 (-8.57%) | 10-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.19  |
1-year : | 4.01 |
| Resists | First : | 2.73 |
Second : | 3.44 |
| Pivot price | 2.2 |
|||
| Supports | First : | 1.6 |
Second : | 1.33 |
| MAs | MA(5) : | 2 |
MA(20) : | 2.47 |
| MA(100) : | 2.8 |
MA(250) : | 4.43 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.4 |
D(3) : | 6.1 |
| RSI | RSI(14): 24.3 |
|||
| 52-week | High : | 10 | Low : | 1.6 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRVO ] has closed below the lower bollinger band by 17.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 21.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.78 - 1.8 | 1.8 - 1.81 |
| Low: | 1.57 - 1.59 | 1.59 - 1.6 |
| Close: | 1.6 - 1.63 | 1.63 - 1.65 |
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant primary progressive aphasia, amyotrophic lateral sclerosis, and amyotrophic lateral sclerosis. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
Thu, 29 Oct 2026
CervoMed Publishes RewinD-LB Results and Neflamapimod Research Findings - TradingView
Thu, 29 Oct 2026
A dementia drug missed its main trial goal. Scans found more volume in one brain region than with placebo. - Stock Titan
Fri, 23 Oct 2026
CervoMed Inc. Estimates – NASDAQ:CRVO - TradingView
Fri, 23 Oct 2026
CRVO News | CERVOMED INC (NASDAQ:CRVO) - ChartMill
Mon, 12 Oct 2026
CervoMed (CRVO) Reports Promising Biomarker Reductions in Phase 2a Trial for Neurodegenerative Disease - GuruFocus
Mon, 12 Oct 2026
CervoMed Shows Progress in Treating Rare Aphasia Condition - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 9.6e+006 (%) |
| Held by Institutions | 26.4 (%) |
| Shares Short | 1,330 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 406.9 % |
| Return on Equity (ttm) | -60.8 % |
| Qtrly Rev. Growth | 331300 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.1 |
| Dividend | 0 |
| Forward Dividend | 1.34e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|